Blood cancer treatment advances saved 25.8 million life-years

More birthdays, graduations and celebrations are the unit that matters in a new estimate of blood cancer progress. Researchers led by Blood Cancer United calculate that treatment advances saved 25.8 million life-years in the United States from 1949 through 2024, turning decades of research into time that patients otherwise might not have had.

The team used the National Cancer Institute’s SEER program — a long-running cancer surveillance database — to compare actual years of life lost with projected losses in the absence of treatment advances. Nearly 20 million life-years were saved among people with Hodgkin lymphoma, acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood cancers, including leukemia, lymphoma and myeloma, make up about 10% of cancer diagnoses in the United States, with more than 192,000 people expected to receive such a diagnosis this year.

The progress has a clear weak spot. Acute myeloid leukemia, or AML, produced the smallest gain in the analysis, at about 720,000 life-years saved, particularly among patients older than 65. Survival disparities also persist: Black patients had worse outcomes across every blood cancer subtype except multiple myeloma. The findings point to areas where new treatments and wider access could make a difference.

And so, concretely? If the current pace of innovation continues, the researchers project 18.9 million additional life-years saved between 2026 and 2040. Accelerating innovation and improving access to treatment could add 1 million more by 2040. These are projections, not promises, and the authors say research investment and affordable care are necessary to keep that trajectory.

The estimate carries important limits. SEER does not provide data before 1975, so the researchers used less robust data to extrapolate earlier mortality and incidence; disease classifications and diagnostic processes also changed over time. Myelodysplastic syndromes and myeloproliferative neoplasms were excluded, meaning the total life-years saved may be underestimated. Blood Cancer United plans an annual report to track progress across blood cancers.